[
    [
        {
            "time": "",
            "original_text": "【药咖君】恒瑞创新药强劲发力，卡瑞利珠单抗肝癌适应症获批；瓜分全球$70亿蛋糕，利伐沙班又一企业入局；武田制药",
            "features": {
                "keywords": [
                    "恒瑞",
                    "创新药",
                    "卡瑞利珠单抗",
                    "肝癌适应症",
                    "利伐沙班",
                    "武田制药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【药咖君】恒瑞创新药强劲发力，卡瑞利珠单抗肝癌适应症获批；瓜分全球$70亿蛋糕，利伐沙班又一企业入局；武田制药",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]